Boehringer flags PhI­II suc­cess for an­oth­er Hu­mi­ra knock­off, set­ting up a crowd­ed field of cheap­er ri­vals — even­tu­al­ly

You can count one more like­ly Hu­mi­ra biosim­i­lar in the grow­ing crowd of ri­vals look­ing to tack­le Ab­b­Vie’s $14 bil­lion fran­chise.

Ger­many’s Boehringer In­gel­heim has lined up pos­i­tive Phase III da­ta for its copy of the Ab­b­Vie block­buster. BI 695501 looked equiv­a­lent in the late-stage rheuma­toid arthri­tis study, in­ves­ti­ga­tors say, and that will like­ly be all it takes to gain an OK for all the in­di­ca­tions Hu­mi­ra is ap­proved for.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.